Clinical trial
Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas
NCT03185494 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- August 1, 2017
- Completion date
- August 1, 2020
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute lymphoblastic leukemia in remission, b-cell adult acute lymphoblastic leukemia, b-cell chronic lymphocytic leukemia in relapse (diagnosis), hematopoietic/lymphoid cancer, prolymphocytic leukemia, recurrent adult diffuse large cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia, stage iii adult diffuse large cell lymphoma, stage iii chronic lymphocytic leukemia, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iv adult diffuse large cell lymphoma, stage iv chronic lymphocytic leukemia, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma